De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Titel:
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Auteur:
Nitz, Ulrike Gluz, Oleg Graeser, Monika Christgen, Matthias Kuemmel, Sherko Grischke, Eva-Maria Braun, Michael Augustin, Doris Potenberg, Jochem Krauss, Katja Schumacher, Claudia Forstbauer, Helmut Reimer, Toralf Stefek, Andrea Fischer, Hans Holger Pelz, Enrico zu Eulenburg, Christine Kates, Ronald Wuerstlein, Rachel Kreipe, Hans Heinrich Harbeck, Nadia